Jupiter Neurosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JUNS research report →
Price Chart
About the company
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation.
- CEO
- Christer Rosen
- IPO
- 2024
- Employees
- 5
- HQ
- Jupiter, FL, US
Get TickerSpark's AI analysis on JUNS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.51M
- P/E
- -0.27
- Fwd P/E
- 1.15
- PEG
- 0.01
- P/S
- 38.73
- P/B
- -7.88
- EV/EBITDA
- -0.29
- Div Yield
- 0.00%
- Gross Margin
- 88.34%
- Op Margin
- -15166.68%
- Net Margin
- -14220.12%
- ROE
- 747.33%
- ROIC
- -709.40%
Latest fiscal year · YoY change
- Revenue
- $21.80K+0.0%
- Gross Profit
- $17.57K+0.0%
- Op Income
- $-8,908,721
- Net Income
- $-8,644,897-254.4%
- EPS
- $-18.75-194.8%
- OCF Growth
- -38.4%
- FCF Growth
- -38.4%
- 52W High
- $138.00
- 52W Low
- $4.56
- 50D MA
- $12.19
- 200D MA
- $42.11
- Beta
- 1.96
- RSI (14)
- 32
- Avg Volume
- 151.92K
No earnings-call transcripts are available for JUNS yet.
- Free Float
- 45.6%
- Shares Outstanding
- 484.67K
- Float Shares
- 221.24K
of shares held by institutions
12 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 248.93K | ▲ 33.10K |
Held by 4 ETFs
Biggest fund positions in JUNS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | Cutler Andrew Jon | other | 472,222 |
| Jul 22, 26 | Cutler Andrew Jon | other | 0 |
| Jun 2, 25 | Kampf Julie B. | other | 82,875 |
| Jun 2, 25 | Kampf Julie B. | other | 82,875 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 96,608 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 164,553 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 164,554 |
| Jun 2, 25 | Rosen Alexander Gustaf Erik | other | 96,608 |
| Mar 2, 26 | Hayward Marshall A. | other | 225,000 |
| Jun 2, 25 | Hayward Marshall A. | other | 399,402 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our JUNS coverage
Recent articles, reports, and earnings notes.
No research on JUNS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JUNS report →Jupiter Neurosciences, Inc. Announces Reverse Stock Split
globenewswire.com · Aug 5
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
globenewswire.com · Jul 21
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
globenewswire.com · Jul 7
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease
globenewswire.com · May 27
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Registered Direct Offering
accessnewswire.com · May 26
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
globenewswire.com · May 21
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
globenewswire.com · May 20
Jupiter Stock Soars After $100 Million ALA-002 Licensing Deal
benzinga.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.